Archive · 27 Jul 2025
Weight Loss Drugs in India: Availability, Cost, and Market Growth
Many actors and celebrities have lost a lot of weight, sparking questions about how they did it.
Some may be using weight-loss drugs, and several are now available in India.
Drugs like Wegovy and Mounjaro are approved for weight loss, while others like Ozempic are not available.
These drugs can be costly, with Wegovy costing between ₹17,345 and ₹26,015 per month.
The market for these drugs is growing fast, and cheaper versions may be available in the future.
Several weight-loss drugs are available in India, including Tirzepatide (Mounjaro), oral Semaglutide, and injectable Semaglutide (Wegovy).
Ozempic is not approved or available in India.
Wegovy has been approved for weight loss in India for people with obesity or overweight and certain children.
The Indian anti-obesity drug market reached ₹628 crore as of June 2024, experiencing rapid growth.
Generic versions of Wegovy are expected to be produced by Indian companies when the patent expires in 2026.
- Who
- Individuals seeking weight loss, pharmaceutical companies
- What
- Availability and costs of weight loss drugs in India
- When
- As of June 2024
- Where
- India
- Why
- To provide information about the market and availability of weight-loss drugs in India.
- Approved Drugs in India
- Tirzepatide (Mounjaro), oral Semaglutide, Wegovy
- Not Approved Drugs
- Ozempic
- Wegovy Monthly Cost
- ₹17,345 to ₹26,015
- Mounjaro Monthly Cost
- ₹14,000 to ₹17,500
- Anti-obesity drug market growth
- Reached ₹628 crore by June 2024
- Wegovy patent expiry
- 2026